Pharmaceutical compositions of levoamlodipine and atorvastatin

A technology of levamlodipine and levamlodipine besylate is applied in the application field of preparing medicines for treating mixed hypertension and hyperlipidemia, and can solve the problems of not clearly showing superiority and the like

Active Publication Date: 2006-10-11
CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD +1
View PDF4 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The patent CN1268052A "therapeutic composition containing amlodipine and atorvastatin" applied by Pfizer of the United States in China, and the CN1117566C "combined drug form containing amlodipine and statin compounds" applied by Pfizer Products Company of the United States, To a certain extent, it expounds the application of compound preparations containing racemic amlodipine in various cardiovascular diseases, but it does not clearly show the superiority brought by this combination of drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The therapeutic effects of the pharmaceutical composition of the present invention on hypertension and hyperlipidemia will be illustrated through animal pharmacodynamic experiments.

[0017] Experimental animal: SD rat

[0018] Experimental method: Two kidneys and one clip were used to make the model, and the average arterial pressure of the rats was measured after feeding with high-sugar feed (standard feed + 25% sucrose) for three weeks. The blood pressure increased by 20mmHg, and the hypertension model was considered successful if it was greater than 115mmHg. .

[0019] Experimental grouping: divided into 8 groups by random method, including: Group A model group (administered with normal saline every day); ; Group C levamlodipine maleate 2.5 mg / kg body weight and atorvastatin hemi-calcium salt 80 mg / kg body weight; group D levamlodipine maleate 5 mg / kg body weight and atorvastatin hemi-calcium salt 20 mg / kg body weight; Group E levamlodipine maleate 5 mg / kg body w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition of Levamlodipine or its medicinal salts and addition salts with Atorvastatin or its medicinal salts, and the use of the pharmaceutical composition in preparing medicament for treating mixed type hypertension and lipidemia.

Description

technical field [0001] The present invention relates to a pharmaceutical composition of levamlodipine or its pharmaceutically acceptable salt and addition salt and atorvastatin or its pharmaceutically acceptable salt, and the preparation of the pharmaceutical composition for treating mixed hypertension and hypertensive Application in lipidemia drugs. technical background [0002] Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, and the conversion of HMG-CoA to mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway. This step is catalyzed by reductase, and inhibin can inhibit HMG-CoA reductase from catalyzing the conversion reaction. Therefore, HMG-CoA reductase inhibitors are effective lipid-lowering agents. [0003] Atorvastatin is a HMG-CoA reductase inhibitor. It itself is inactive, and the hydrolyzate after oral absorption competitively inhibits the rate-limiting enzyme hydroxymethylg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4422A61P9/12A61P3/06A61K31/40
Inventor 刘振涛张宏武申东民冯小龙杨丽英梁敏刘海丽
Owner CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap